Rituximab as monotherapy for the treatment of chronic active antibody-mediated rejection after kidney transplantation

Transpl Int. 2018 Apr;31(4):451-455. doi: 10.1111/tri.13111. Epub 2018 Jan 30.

Affiliations

¹ Transplantation Center, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
² Service of Clinical Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.
³ Service of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.

PMID: 29328536
DOI: 10.1111/tri.13111

No abstract available

Publication types

Letter

MeSH terms

Adult
Female
Graft Rejection / drug therapy*
Graft Rejection / immunology
Humans
Immunologic Factors / therapeutic use*
Kidney Transplantation / adverse effects*
Male
Middle Aged
Retrospective Studies
Rituximab / therapeutic use*
Young Adult

Substances

Immunologic Factors
Rituximab